Clinical impact of post-progression survival in patients with locally advanced non-small cell lung cancer after chemoradiotherapy
Article Category: Research Article
Published Online: Feb 25, 2022
Page range: 228 - 237
Received: Nov 02, 2021
Accepted: Jan 13, 2022
DOI: https://doi.org/10.2478/raon-2022-0006
© 2022 Hisao Imai, Daijiro Kobayashi, Kyoichi Kaira, Sayaka Kawashima, Ken Masubuchi, Masumi Murata, Takeshi Ebara, Yoshizumi Kitamoto, Koichi Minato, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Background
The efficacy of first-line chemoradiotherapy for overall survival (OS) might be confounded by the subsequent treatments in patients with locally advanced non-small cell lung cancer (NSCLC). In this study, we assessed the associations of progression-free survival (PFS) and post-progression survival (PPS) with OS after chemoradiotherapy for locally advanced NSCLC using patient-level data.
Patients and methods
Between January 2011 and December 2018, 45 patients with locally advanced NSCLC who had received first-line chemoradiotherapy and in whom recurrence occurred were analysed. The associations of PFS and PPS with OS were analysed at the individual level.
Results
Linear regression and Spearman rank correlation analyses revealed that PPS was strongly correlated with OS (
Conclusions
The current analysis of individual-level data of patients treated with first-line chemoradiotherapy implied that PPS had a higher impact on OS than PFS in patients with locally advanced NSCLC. Additionally, current perceptions indicate that treatment beyond progression after first-line chemoradiotherapy might strongly affect OS.